Inventaire - teman dan komunitas anda adalah perpustakaan terbaik

Developing models for cachexia and their implications in drug discovery

pengarang

Stephan von Haehling

Stefan D. Anker

1965 -

diterbitkan dalam: Expert Opinion on Drug Discovery

tanggal publikasi: 2015-04-30

bahasa: Inggris

subyek utama: drug discovery

Cites articles 91

Date

Judul

Pengarang

2015-01-01

Muscle wasting in disease: molecular mechanisms and promising therapies

Shenhav Cohen, James A Nathan
2014-12-01

Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014

Stephan von Haehling, Stefan D. Anker
2014-10-09

Cancer cachexia: understanding the molecular basis

Josep M. Argilés, Sílvia Busquets, Britta Stemmler, Francisco Javier López-Soriano
2014-04-23

Quercetin supplementation attenuates the progression of cancer cachexia in ApcMin/+ mice

Reilly Enos, James A. Carson
2014-03-21

Systemic inflammation promotes lung metastasis via E-selectin upregulation in mouse breast cancer model
2014-10-01

HIF transcription factors, inflammation, and immunity

Victor Nizet, Randall S. Johnson, Asis Palazon
2014-02-12

Extracellular superoxide dismutase ameliorates skeletal muscle abnormalities, cachexia, and exercise intolerance in mice with congestive heart failure

Kyle S Martin, Jarrod A. Call, Brent A French, Christopher M Rembold
2014-10-28

Catabolic signaling and muscle wasting after acute ischemic stroke in mice: indication for a stroke-specific sarcopenia

Ulrich Dirnagl, Stephan von Haehling, Andreas Meisel, Stefan D. Anker, Anika Tschirner, Wolfram Doehner, Nadja Scherbakov
2014-09-06

Neuroprotective agents target molecular mechanisms of disease in ALS.

Merit E Cudkowicz
2014-03-31

Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
2014-04-07

Novel investigational biologics for the treatment of cancer cachexia
2014-07-17

A switch from white to brown fat increases energy expenditure in cancer-associated cachexia.

Stefan Rose-John, Rudolf Zechner, Erwin F. Wagner, Renate Schreiber, Ramón Campos-Olivas, Martina Schweiger, Mercedes Rincón
2014-07-13

Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia

Vickie E. Baracos, Bruce Spiegelman
2014-09-01

Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer.

Stephan von Haehling, Hubert Scharnagl, Stefan D. Anker, Wolfram Doehner, Anja Sandek, Larissa Cramer, Hanno Riess, Tatjana Stojakovic
2014-04-09

Systems-based discovery of tomatidine as a natural small molecule inhibitor of skeletal muscle atrophy

Daniel P Cook, Christopher M Adams
2014-06

The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats

Stephan von Haehling, Stefan D. Anker, Andrew Coats, Mareike S Pötsch, Anika Tschirner, Sandra Palus, Wolfram Doehner
2014-04-23

Animal models of chronic obstructive pulmonary disease

Michael Fricker, Andrew Deane
2013-09-21

The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review
2013-06

Cancer cachexia: impact, mechanisms and emerging treatments
2013-06-26

Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia

Gordon S. Lynch, Daniel J. Ham, Kate T Murphy, Rene Koopman
2013-03-26

Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.
2013-12-15

Characterization of the male ApcMin/+ mouse as a hypogonadism model related to cancer cachexia

James A. Carson
2013-01-01

Inhibitory effects of isoflavones on tumor growth and cachexia in newly established cachectic mouse models carrying human stomach cancers
2013-12-17

New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line

Hirofumi Hashimoto
2013-05-16

Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis
2013-03-31

Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies

Charles Erlichman, Donald W Northfelt
2013-08-13

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours

Alexander J. Lazar, Charles Rudin
2013-08-29

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure

Thomas Force, Stephan von Haehling, Hind Lal, Frederic Jaisser, Thomas Thum, Berthold Hocher, Stefan D. Anker, Elena Kaschina, Denise Hilfiker-Kleiner, Andrew Coats, Mareike S Pötsch, Anika Tschirner, Sandra Palus, Wolfram Doehner, Karoline von Websky, Josep M. Argilés
2013-06-14

The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy.

Stephan von Haehling, Stefan D. Anker, Anika Tschirner, Wolfram Doehner, Kai Hartman
2013-10-12

Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia

Stephan von Haehling, Stefan D. Anker, Andrew Coats, Anika Tschirner, Sandra Palus, Wolfram Doehner, Yulia Elkina
2013-03-29

Cachexia as a major public health problem: frequent, costly, and deadly

Kamyar Kalantar-Zadeh, Stephan von Haehling, Stefan D. Anker, Mitja Lainscak
2013-01-27

TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy.

Thomas Thum, Stephan von Haehling, Stefan D. Anker, Roland Hetzer, Anika Tschirner, Wolfram Doehner, Markus S Anker

Artikel - wd:Q38451282

Selamat datang di Inventaire

perpustakaan teman-teman dan komunitas anda

pelajari lebih lanjut